Prostate Cancer - Results from #1900

Sumitomo Pharma Announces Authorization in Canada of ORGOVYX® (relugolix) for the Treatment of Men with Advanced Prostate Cancer October 23, 2023

Deep Learning-Based Interpretable AI for Prostate T2W MRI Quality Evaluation. October 23, 2023

PSMA-PET in Addition to mpMRI and Biopsies to Select Prostate Cancer Patients for Focal Therapy. October 23, 2023

Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy. October 23, 2023

Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide. October 23, 2023

Analysis of active surveillance uptake for localized prostate cancer in Quebec in 2016: A Canadian bicentric study and comparison with 2010 data. October 23, 2023

Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists. October 20, 2023

Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer. October 20, 2023

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. October 20, 2023

Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade. October 20, 2023

Health-Related Quality of Life Assessment in Prostate Cancer Patient Undergoing Androgen Deprivation Therapy: Real-World Experience in the READT Study. October 20, 2023

Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort. October 19, 2023

Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. October 19, 2023

Comparative analysis of robot-assisted and open approach for PSMA-radioguided surgery in recurrent prostate cancer. October 19, 2023

Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer. October 19, 2023

Quantitative [68Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study. October 19, 2023

Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE). October 18, 2023

Radioligand Therapy With 177Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer: Oncological Outcomes and Toxicity Profile. October 18, 2023

Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. October 18, 2023

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. October 18, 2023

Page 96 of 1435